Phospho-Tau (tyr 18)

Tauopathies are a group of diverse dementias and movement disorders which have a common pathological feature in that they all display the presence of intracellular accumulation of abnormal filaments of Tau protein. While the abnormal phosphorylation of Tau on serine and threonine has been well established in the disease process, its phosphorylation on tyrosine 18 has only recently been described as present in Alzheimer’s disease (AD) brain.

Phosphorylated Tau

Peptide

The antibody recognizes the human Phospho-Tau protein at the tyrosine 18 phosphorylation site with no detectable cross-reactivity.

9G3

IgG2a

None

Purified with protein G, stored in PBS pH 7.4 and lyophilized.

If reconstituted with deionized water in 100 µl: WB 1:1000-1:5000; IHC 1:1000-1:5000, IF 1:200-1:5000. Optimal dilution has to be determined by the user.

Research Use Only

Lyophilized antibodies can be kept at 4ºC for up to 3 months and should be kept at -20ºC for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80ºC) or kept at 4ºC for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy. To limit antibody loss or degradation, BSA (final concentration 1%) and sodium azide (final concentration 0.02%) can be added to the suggested first dilution. It is important to first verify if those preservatives are compatible with your assay.